Rodent model

A rodent model is a laboratory study conducted in rats or mice, forming the preclinical scaffold of most pharmacological knowledge about the compounds in this index. Before a substance is tested in humans — and in many cases instead of being tested in humans — it is first characterised in rodents.

Common paradigms include drug discrimination (whether an animal identifies a compound as similar to a reference drug), locomotor activity (stimulant or sedative effects on movement), self-administration (whether an animal will work to obtain the substance, indicating reinforcing potential), conditioned place preference, and tissue distribution studies that map where a compound travels in the body after dosing.

Rodents sit at the base of the preclinical evidence hierarchy. Findings from rodent work generate hypotheses that inform human research; they are rarely sufficient on their own to characterise what a compound does in people.

What this design can establish

A well-conducted rodent study can establish that a compound produces measurable pharmacological effects in that species: that it crosses the blood-brain barrier, modulates a receptor, alters locomotion, acts as a reinforcer, or is lethal above a certain dose in a rodent population. It can define dose-response relationships within the species and identify metabolites along with their relative activity.

Discriminative stimulus studies are particularly useful for mapping receptor mechanisms. If a novel compound fully substitutes for a known reference drug in trained animals, this strongly suggests shared receptor pharmacology — giving researchers a mechanistic handle before any human data exists.

Rodent self-administration is the best-validated preclinical index of abuse liability. It predicts, at a population level, whether a class of compounds tends to be reinforcing in humans — even when the schedules and doses used in rodents differ substantially from typical human patterns.

What it cannot

A rodent finding cannot establish that a compound produces the same effects in humans, at equivalent doses, or through equivalent mechanisms. Rodents differ from people in metabolic enzymes, density and subtype distribution, and body mass. The routes commonly used in rodent studies — often intraperitoneal injection — and the mg/kg doses involved diverge sharply from human exposure patterns.

The inference a reader is most likely to make — that toxicity, dependence potential, or perceptual effects observed in rodents will map directly onto people — may be directionally suggestive but cannot be read as confirmation. Some compounds with strong rodent reinforcement signals see little human misuse; others with weak rodent profiles prove clinically significant.

For many novel psychoactive substance, a handful of rodent studies constitute the entire published record. The evidential frame matters: observed in rats at intraperitoneal doses is a different claim from expected in humans at typical exposure. The absence of human data does not make a rodent finding more generalisable — it makes the gap explicit.